CHGA has been approved as a powerful biomarker for the early detection of various digestive system carcinomas, including gastric cancer (Yang and Chung, 2008), pancreatic neuroendocrine tumors (Weisbrod et al., 2013), and colorectal cancer (Zhang et al., 2019). The gene discussed is CHGA; the disease is pancreatic neuroendocrine tumor.